Increased ratio of anti-apoptotic to pro-apoptotic Bcl2 gene-family members in lithium-responders one month after treatment initiation

Biology of Mood & Anxiety Disorders

Lori Lowthert⁵  Janine Leffert⁵  Aiping Lin²  Sheila Umlauf⁴  Kathleen Maloney⁵  Anjana Muralidharan⁵  Boris Lorberg⁵  Shrikant Mane⁴  Hongyu Zhao³  Rajita Sinha⁵  Zubin Bhagwagar¹  Robert Beech⁵ 

[1] Neuroscience Global Clinical Research, Bristol-Myers Squibb, Wallingford, CT, 06492-1996, USA

[2] Keck Foundation Biotechnology Biostatistics Resource, New Haven, CT, 06511, USA

[3] Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT, 06511, USA

[4] Center for Genome Analysis, New Haven, CT, 06511, USA

[5] Department of Psychiatry, New Haven, CT, 06511, USA

关键词: Mitochondria;    Apoptosis;    BCL2;    Gene expression;    Lithium-response;    Microarray;    Bipolar disorder;   

Others  :  797814
DOI  :  10.1186/2045-5380-2-15

 received in 2012-06-10, accepted in 2012-08-15,  发布年份 2012

【 摘 要 】

Background

Lithium is considered by many as the gold standard medication in the management of bipolar disorder (BD). However, the clinical response to lithium is heterogeneous, and the molecular basis for this difference in response is unknown. In the present study, we sought to determine how the peripheral blood gene expression profiles of patients with bipolar disorder (BD) changed over time following intitiation of treatment with lithium, and whether differences in those profiles over time were related to the clinical response.

Methods

Illumina Sentrix Beadchip (Human-6v2) microarrays containing > 48,000 transcript probes were used to measure levels of expression of gene-expression in peripheral blood from 20 depressed subjects with BD prior to and every two weeks during 8 weeks of open-label treatment with lithium.

Changes in gene-expression were compared between treatment responders (defined as a decrease in the Hamilton Depression Rating Scale of 50% or more) and non-responders. Pathway analysis was conducted using GeneGO Metacore software.

Results

127 genes showed a differential response in responders vs. non-responders. Pathway analysis showed that regulation of apoptosis was the most significantly affected pathway among these genes. Closer examination of the time-course of changes among BCL2 related genes showed that in lithium-responders, one month after starting treatment with lithium, several anti-apoptotic genes including Bcl2 and insulin receptor substrate 2 (IRS2) were up-regulated, while pro-apoptotic genes, including BCL2-antagonist/killer 1 (BAK1) and BCL2-associated agonist of cell death (BAD), were down-regulated. In contrast, in lithium non-responders, BCL2 and IRS2 were down-regulated, while BAK1 and BAD up-regulated at the one-month time-point.

Conclusions

These results suggest that differential changes in the balance of pro- and anti- apoptotic gene-expression following treatment with lithium may explain some of the heterogeneity in clinical response in BD patients.

【 授权许可】

   
2012 Lowthert et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M, Kessler RC: Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 2007, 64:543-552.
• [2]Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE: Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005, 62:593-602.
• [3]Waraich P, Goldner EM, Somers JM, Hsu L: Prevalence and incidence studies of mood disorders: a systematic review of the literature. Can J Psychiatry 2004, 49:124-138.
• [4]Martinowich K, Schloesser RJ, Manji HK: Bipolar disorder: from genes to behavior pathways. J Clin Invest 2009, 119:726-736.
• [5]Cade JF: Lithium salts in the treatment of psychotic excitement. Med J Aust 1949, 2:349-352.
• [6]APA: Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002, 159:1-50.
• [7]Grof P, Muller-Oerlinghausen B: A critical appraisal of lithium's efficacy and effectiveness: the last 60 years. Bipolar Disorders 2009, 11:10-19.
• [8]Gershon S, Chengappa KN, Malhi GS: Lithium specificity in bipolar illness: a classic agent for the classic disorder. Bipolar Disord 2009, 11(Suppl 2):34-44.
• [9]Tondo L, Hennen J, Baldessarini RJ: Lower suicide risk with long-term lithium treatment in major affective illness: a meta-analysis. Acta Psychiatr Scand 2001, 104:163-172.
• [10]Ernst CL, Goldberg JF: Antisuicide properties of psychotropic drugs: a critical review. Harv Rev Psychiatry 2004, 12:14-41.
• [11]Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D: Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 2003, 290:1467-1473.
• [12]Michelon L, Meira-Lima I, Cordeiro Q, Miguita K, Breen G, Collier D, Vallada H: Association study of the INPP1, 5HTT, BDNF, AP-2beta and GSK-3beta GENE variants and restrospectively scored response to lithium prophylaxis in bipolar disorder. Neurosci Lett 2006, 403:288-293.
• [13]Bremer T, Diamond C, McKinney R, Shehktman T, Barrett TB, Herold C, Kelsoe JR: The pharmacogenetics of lithium response depends upon clinical co-morbidity. Mol Diagn Ther 2007, 11:161-170.
• [14]Perlis RH, Smoller JW, Ferreira MA, McQuillin A, Bass N, Lawrence J, Sachs GS, Nimgaonkar V, Scolnick EM, Gurling H, et al.: A genomewide association study of response to lithium for prevention of recurrence in bipolar disorder. Am J Psychiatry 2009, 166:718-725.
• [15]Schulze TG, Alda M, Adli M, Akula N, Ardau R, Bui ET, Chillotti C, Cichon S, Czerski P, Del Zompo M, et al.: The International Consortium on Lithium Genetics (ConLiGen): an initiative by the NIMH and IGSLI to study the genetic basis of response to lithium treatment. Neuropsychobiology 2010, 62:72-78.
• [16]Belmaker RH, Agam G: Bipolar disorder: Neurochemistry and drug mechanisms. Discov Med 2005, 5:191-198.
• [17]Chen G, Zeng WZ, Yuan PX, Huang LD, Jiang YM, Zhao ZH, Manji HK: The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J Neurochem 1999, 72:879-882.
• [18]Manji HK, Moore GJ, Chen G: Lithium up-regulates the cytoprotective protein Bcl-2 in the CNS in vivo: a role for neurotrophic and neuroprotective effects in manic depressive illness. J Clin Psychiatry 2000, 61(Suppl 9):82-96.
• [19]Bachmann RF, Wang Y, Yuan P, Zhou R, Li X, Alesci S, Du J, Manji HK: Common effects of lithium and valproate on mitochondrial functions: protection against methamphetamine-induced mitochondrial damage. Int J Neuropsychopharmacol 2009, 12:1-18.
• [20]Manji HK, Moore GJ, Chen G: Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness. Biol Psychiatry 2000, 48:740-754.
• [21]Einat H, Manji HK: Cellular Plasticity Cascades: Genes-To-Behavior Pathways in Animal Models of Bipolar Disorder. Biol Psychiatry 2006, 59:1160-1171.
• [22]Beech RD, Lowthert L, Leffert JJ, Mason PN, Taylor MM, Umlauf S, Lin A, Lee JY, Maloney K, Muralidharan A, et al.: Increased peripheral blood expression of electron transport chain genes in bipolar depression. Bipolar Disord 2010, 12:813-824.
• [23]APA: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR). American Psychiatric Association, Washington, DC; 2000.
• [24]First MB, Spitzer RL, Gibbon M, Williams J: Structured Clinical Interview for DSM-IV Axis I Disorders — Patient Edition (SCID-I/P, Version 2.0). Biometrics Research Department, New York State Psychiatric Institute, New York; 1996.
• [25]Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960, 23:56-62.
• [26]Mazure C, Nelson JC, Price LH: Reliability and validity of the symptoms of major depressive illness. Arch Gen Psychiatry 1986, 43:451-456.
• [27]Montgomery SA, Asberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979, 134:382-389.
• [28]Hamilton M: The assessment of anxiety states by ratings. Br J Med Psychol 1959, 32:50-55.
• [29]Young RC, Biggs JT, Ziegler VE, Meyer DA: A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978, 133:429-435.
• [30]Illumina: BeadStudio Gene Expression Module v32 User Guide. In Chapter 4: Normalization and Differential Analysis. 2009 edition. Illumina Technical Support, San Diego, CA; 2009.
• [31]Barnes M, Freudenberg J, Thompson S, Aronow B, Pavlidis P: Experimental comparison and cross-validation of the Affymetrix and Illumina gene expression analysis platforms. Nucleic Acids Res 2005, 33:5914-5923.
• [32]Reiner A, Yekutieli D, Benjamini Y: Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics 2003, 19:368-375.
• [33]Storey JD, Xiao W, Leek JT, Tompkins RG, Davis RW: Significance analysis of time course microarray experiments. Proc Natl Acad Sci U S A 2005, 102:12837-12842.
• [34]Malhi GS, Adams D, Berk M: Medicating mood with maintenance in mind: bipolar depression pharmacotherapy. Bipolar Disord 2009, 11(Suppl 2):55-76.
• [35]Danial NN, Korsmeyer SJ: Cell death: critical control points. Cell 2004, 116:205-219.
• [36]Adams JM, Cory S: Bcl-2-regulated apoptosis: mechanism and therapeutic potential. Curr Opin Immunol 2007, 19:488-496.
• [37]Ueno H, Kondo E, Yamamoto-Honda R, Tobe K, Nakamoto T, Sasaki K, Mitani K, Furusaka A, Tanaka T, Tsujimoto Y, et al.: Association of insulin receptor substrate proteins with Bcl-2 and their effects on its phosphorylation and antiapoptotic function. Mol Biol Cell 2000, 11:735-746.
• [38]Andreazza AC, Shao L, Wang JF, Young LT: Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder. Arch Gen Psychiatry 2010, 67:360-368.
• [39]Maurer IC, Schippel P, Volz HP: Lithium-induced enhancement of mitochondrial oxidative phosphorylation in human brain tissue. Bipolar Disord 2009, 11:515-522.
• [40]Rezin GT, Cardoso MR, Goncalves CL, Scaini G, Fraga DB, Riegel RE, Comim CM, Quevedo J, Streck EL: Inhibition of mitochondrial respiratory chain in brain of rats subjected to an experimental model of depression. Neurochem Int 2008, 53:395-400.
• [41]Hunsberger JG, Machado-Vieira R, Austin DR, Zarate C, Chuang DM, Chen G, Reed JC, Manji HK: Bax inhibitor 1, a modulator of calcium homeostasis, confers affective resilience. Brain Res 2011, 1403:19-27.
• [42]Shaltiel G, Chen G, Manji HK: Neurotrophic signaling cascades in the pathophysiology and treatment of bipolar disorder. Curr Opin Pharmacol 2007, 7:22-26.
• [43]Hunsberger JG, Austin DR, Chen G, Manji HK: Cellular mechanisms underlying affective resiliency: the role of glucocorticoid receptor- and mitochondrially-mediated plasticity. Brain Res 2009, 1293:76-84.